Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
59 participants
INTERVENTIONAL
2020-07-01
2020-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers
NCT05381207
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*
NCT01240889
A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)
NCT00968149
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
NCT00092885
Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
NCT00972738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early interventional treatment group
The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Post-onset treatment group
The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.
10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Control group
The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
No oral drug therapy throughout the pollen period
Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.
10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
No oral drug therapy throughout the pollen period
Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* had not received any therapies for AR or antibiotics for at least 4 weeks before their outpatient clinic visit prior to the study
* all of the subjects in the study reside in Beijing.
Exclusion Criteria
* pregnant women and minors
18 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tongren Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhang Luo
Role: PRINCIPAL_INVESTIGATOR
Beijing Institute of Otolaryngology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TR-Early intervention
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.